In addition, the hepatic gene expression data agreed with reports showing the upregulation of Pparγ in MR rats [7] and its target genes: Cd36 and Atgl. In fact, rosiglitazone, a Pparγ agonist, was reported to ameliorate hepatic steatosis and improve insulin sensitivity [16], [35]–[38]. This evidence concerns the gene INS and fatty liver disease.